SUMMARY The place of sulphasalazine in the management of rheumatoid arthritis over prolonged periods of time has been compared and contrasted with that of sodium aurothiomalate. One hundred and forty-three patients (59 on sulphasalazine, 84 on sodium aurothiomalate) have been treated for periods of up to 42 months. Sulphasalazine is highly effective for some patients, though probably less frequently than sodium aurothiomalate. However, its safety profile is far superior, and very long-term treatment with sulphasalazine is a safe option for treatment of rheumatoid arthritis.
Sodium aurothiomalate therapy has an established place in the management of rheumatoid arthritis and, despite the wide range of toxic effects which complicate its use, many rheumatologists would agree that it can produce profound benefits for some patients. It has been used for far longer than other members of the group of remission-inducing or second-line antirheumatic drugs and has therefore set standards against which other therapies may be measured. Recently it has been suggested that sulphasalazine (salicyl-azo-sulphapyridine) should be considered to be an additional member of this group, -5 though these open and controlled clinical trials were too short, all being 12 months or less, to permit firm conclusions to be made about its place in the long-term treatment of rheumatoid arthritis.
We have examined the frequency of success and the reasons for failure of sulphasalazine therapy in a large group of rheumatoid patients where the potential treatment periods ranged from 24 to 42 months. To Sulphasalazine was administered as the enteric coated preparation and was introduced at 1 g daily, increasing to 2 g daily after one week and continued at this dose indefinitely. Mild unwanted reactions were managed by dose reduction or by a slower increase to the maintenance dose. Some patients were taking oral corticosteroids but had been on a stable dose before starting sodium aurothiomalate or sulphasalazine, and this was continued unchanged or reduced if their clinical state allowed. A number of patients were admitted to hospital and some received intra-articular injections. In almost every case these events occurred early during the period of sodium aurothiomalate or sulphasalazine therapy.
The statistical analyses used were Student's t test for comparing paired data, the x2 test, and logistic regression methods.6 Statistical significance was taken as p<005.
Results
The two groups of patients were broadly similar before treatment ( Table 2) .
32% of the sulphasalazine group and 44% of the sodium aurothiomalate group had had a highly satisfactory long-term response. Fifteen of 19 good responders in the sulphasalazine group and 29 of 37 in the sodium aurothiomalate group satisfied the American Rheumatism Association criteria for com- plete remission of disease' and had done so for more than one year (Table 3) . There were significant falls in erythrocyte sedimentation rate with both drugs, reflecting the observed clinical improvement (Table 4) . With sodium aurothiomalate all groups showed a fall in erythrocyte sedimentation rate during therapy, whereas with sulphasalazine only those patients classified as having a successful or partially successful outcome to treatment showed a significant fall.
Almost half of the patients in both groups discontinued therapy within two years and therefore failed to gain long-term benefits. Treatment Table 5 .
Seropositivity, sex, disease duration, periods of inpatient therapy, the use of intra-articular or oral corticosteroids, and initial erythrocyte sedimentation rate had no significant influence on the eventual outcome (Table 6 ). The only previous long-term follow up study of patients with rheumatoid arthritis treated with sulphasalazine was reported by Svartz in 1948.8 However, her study was different from ours, since most of her patients received only a short course of sulphasalazine during a period of hospital treatment; after discharge from hospital they were assessed between two and six and a half years later. replaced. In such situations sulphasalazine was reported to be as efficacious as sodium aurothiomalate or penicillamine, but from these studies it is not possible to determine the frequency of sustained significant improvement with sulphasalazine.
Unlike these recent studies we have examined the efficacy of sulphasalazine and sodium aurothiomalate against the varied background of normal clinical practice. The only exclusion for sulphasalazine was a patient with a recent history of severe dyspepsia, and none arose for sodium aurothiomalate. By adopting simple though stringent criteria for treatment outcome we have been able to identify the proportion of patients achieving a satisfactory outcome and maintaining it for long periods. This was not a randomised prospective trial, but all patients were treated for similar reasons by the same physician, and we therefore felt it reasonable to examine our long-term experience with these drugs. There was a trend for men to do better than women, especially with sulphasalazine (Table 6 ), but this difference did not reach statistical significance.
The erythrocyte sedimentation rate was not used to determine whether drug therapy should be started nor did it influence the classification of treatment outcome. We nevertheless examined the changes in the erythrocyte sedimentation rate during treatment to see whether they complemented the clinical observations. Significant falls were seen only in those sulphasalazine treated patients considered to have shown a favourable long-term response, whereas with sodium aurothiomalate the erythrocyte sedimentation rate fell significantly in all treatment outcome groups (Table 4) . This presumably reflects the fact that withdrawal from sodium aurothiomalate usually occurred because of problems of toxicity despite improvement in the arthritis, whereas sulphasalazine was generally stopped for lack of efficacy.
The results suggest that when sulphasalazine works well the outcome is similar to that observed with therapy with sodium aurothiomalate. Prolonged disease remission is seen in a substantial minority of patients treated with either drug. Primary treatment failure with sulphasalazine is much more frequent than with sodium aurothiomalate, but the safety profile of sulphasalazine is far superior. Treatment failure with sulphasalazine can generally be identified within three months,2 4 and it is now our policy to use sulphasalazine before sodium aurothiomalate, thus ensuring that at least one third of our patients are not exposed to the much greater hazards of sodium aurothiomalate therapy.
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